| pubmed-article:2964529 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2964529 | lifeskim:mentions | umls-concept:C0042397 | lld:lifeskim |
| pubmed-article:2964529 | lifeskim:mentions | umls-concept:C0005210 | lld:lifeskim |
| pubmed-article:2964529 | lifeskim:mentions | umls-concept:C0036983 | lld:lifeskim |
| pubmed-article:2964529 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2964529 | pubmed:dateCreated | 1988-4-12 | lld:pubmed |
| pubmed-article:2964529 | pubmed:abstractText | A relationship between increased peripheral resistance (TPRI) and decreased cardiac index (CI) and mortality from sepsis has been suggested. The relationship between endogenous opiates and this response was evaluated. Methods: Chronically instrumented sheep were given E. coli endotoxin (LPS, 1.5 mcg/kg x 30 minutes). In one study, survivors (n = 9) and nonsurvivors (n = 11) of LPS were compared along with survivors (n = 8) of half the dose of LPS. In a second study, two groups of animals received naloxone: one (n = 11) had a bolus of 2 mg/kg followed by a 2 mg/kg/hr continuous infusion started 30 minutes before LPS while the other had the bolus and infusion started 1 hour after LPS was begun. Results: Both vasoconstrictive and vasodilative phases were seen. Vasoconstriction was associated with elevated beta endorphin levels, a pattern sustained until death in the nonsurvivors. Both pre- and posttreatment with naloxone lessened the maximum increase in total peripheral resistance index compared with untreated sheep. Discussion: The vasoconstrictive aspects of the response to LPS correlated with elevated beta endorphin levels and with mortality. This vascular response is attenuated with naloxone blockade. | lld:pubmed |
| pubmed-article:2964529 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2964529 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2964529 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2964529 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2964529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2964529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2964529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2964529 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2964529 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:2964529 | pubmed:issn | 0022-5282 | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:KimuraRR | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:DavenportSS | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:TraberLL | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:HerndonDD | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:TraberDD | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:DottHH | lld:pubmed |
| pubmed-article:2964529 | pubmed:author | pubmed-author:LubbesmeyerHH | lld:pubmed |
| pubmed-article:2964529 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2964529 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:2964529 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2964529 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2964529 | pubmed:pagination | 131-9 | lld:pubmed |
| pubmed-article:2964529 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:meshHeading | pubmed-meshheading:2964529-... | lld:pubmed |
| pubmed-article:2964529 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2964529 | pubmed:articleTitle | Beta endorphin, a vasoconstrictor during septic shock. | lld:pubmed |
| pubmed-article:2964529 | pubmed:affiliation | Department of Anesthesiology, Surgery, University of Texas Medical Branch, Galveston. | lld:pubmed |
| pubmed-article:2964529 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2964529 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
